Bard ends deal with drugs-for-devices firm Angiotech:
This article was originally published in Clinica
CR Bard and Angiotech Pharmaceuticals have, "by mutual agreement", ended a collaboration to develop a paclitaxel-loaded "vascular wrap". Vancouver, Canada-based Angiotech said the five-year partnership was ended because the device firm did not usually invest in such long-term, expensive programmes. Having been responsible for development of the product, which is designed to treat stenosis in peripheral vascular surgery, Angiotech says it will be able to continue the programme independently with no delays or disruptions. Angiotech's most high-profile drug-device partnership to date is with Boston Scientific, which is hoping to launch its paclitaxel-coated stent in the US next year.